Rapid improvement of disseminated intravascular coagulation by donor leukocyte infusions in a patient with promyelocytic crisis of chronic myelogenous leukemia after reduced-intensity stem cell transplantation from an HLA 2-antigen-mismatched mother

International Journal of Hematology

Volumn 77, Issue 4, 2003, Pages 408-411

  Matsue, Kosei ^a,b   Yamada, Konagi ^a   Takeuchi, Masami ^a   Tabayashi, Takayuki ^a  

^a Kameda General Hospital   (Japan)

^b Kameda General Hospital   (Japan)

Author keywords

CML; DIC; DLI; Promyelocyte; Reduced intensity transplantation

Indexed keywords

CYTARABINE; CYTOTOXIC AGENT; FLUDARABINE; HLA ANTIGEN CLASS 2; IDARUBICIN; LYMPHOGLOBULINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; RETINOIC ACID; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DISEASE EXACERBATION; DISSEMINATED INTRAVASCULAR CLOTTING; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; LEUKOCYTE; LEUKOCYTE COUNT; MALE; PROMYELOCYTE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0141569502     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982653     Document Type: Article

References (19)

1. Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
2. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 1995;86:2041-2050.
3. Matsue K, Tabayashi T, Yamada K, Takeuchi M. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant. 2002;29:63-66.
4. Keil F, Kalhs P, Haas OA, et al. Relapse of Philadelphia chromosome positive acute lymphoblastic leukaemia after marrow transplantation: sustained molecular remission after early and dose-escalating infusion of donor leucocytes. Br J Haematol. 1997;97:161-164.
5. Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood. 2001;97:2574-2579.
6. Rosenthal NS, Knapp D, Farhi DC. Promyelocytic blast crisis of chronic myelogenous leukemia: a rare subtype associated with disseminated intravascular coagulation. Am J Clin Pathol. 1995;103:185-188.
7. Misawa S, Lee E, Scheffer CA, Liu Z, Testa JR. Association of the translocation (15;17) with malignant proliferation of promyelocytes in acute leukemia and chronic myelogenous leukemia at blast crisis. Blood. 1986;67:270-274.
8. Scolnik MP, Palacios MF, Acevedo SH, et al. Promyelocytic blast crisis of chronic myelogenous leukemia with translocations (9;22) and (15;17). Leuk Lymphoma. 1998;31:231-236.
9. Mitterbauer G, Nemeth P, Wacha S, et al. Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction. Br J Haematol. 1999;106:634-43.
10. Cassinat B, Zassadowski F, Balitrand N, et al. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia. 2000;14:324-328.
11. Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73:1720-1728.
12. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995;86:1261-1268.
13. Moretta A, Moretta L. HLA class I specific inhibitory receptors. Curr Opin Immunol. 1997;9:694-701.
14. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333-339.
15. Ruggeri L, Capanni M, Martelli MF, Velardi A. Cellular therapy: exploiting NK cell alloreactivity in transplantation. Curr Opin Hematol. 2001;8:355-359.
16. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2100.
17. Evans PC, Lambert N, Maloney S, et al. Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma. Blood. 1999;93:2033-2037.
18. Tamaki S, Ichinohe T, Matsuo K, et al. Superior survival of blood and marrow stem cell recipients given maternal grafts over recipients given paternal grafts. Bone Marrow Transplant. 2001;28:375-380.
19. van Rood JJ, Loberiza FR Jr, Zhang MJ, et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood. 2002;99:1572-1577.